Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. (Q34982142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

review article

1 reference

title

Lung cancer--where are we today? Current advances in staging and nonsurgical treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

author name string

Stephen G Spiro

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

language of work or name

English

0 references

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

14 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

1166-1196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

Mortality in relation to smoking: 20 years' observations on male British doctors

14 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Smoking and carcinoma of the lung; preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Differences in lung cancer risk between men and women: examination of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

All-cause mortality in randomized trials of cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Mass screening for lung cancer with mobile spiral computed tomography scanner

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Early Lung Cancer Action Project: overall design and findings from baseline screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The natural history of lung cancer: A review based on rates of tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Paradoxic pulmonary vasoconstriction in response to acetylcholine in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Age and the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Bronchus sign on CT in peripheral carcinoma of the lung: value in predicting results of transbronchial biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Diagnosis of lung cancer: FOB before CT or CT before FOB?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Role of computed tomographic scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Can computed tomography of the chest stage lung cancer? Yes and no.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Detecting mediastinal lymph node metastases in non-small-cell lung cancer using a combination of technetium-99m tetrofosmin chest single photon emission computed tomography and chest computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Tumor invasion of the chest wall in lung cancer: diagnosis with US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Staging non-small cell lung cancer with whole-body PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of the Wang 19-gauge and 22-gauge needles in the mediastinal staging of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endobronchial ultrasonography for mediastinal and hilar lymph node metastases of lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Obtaining tissue from the mediastinum: endoscopic ultrasound guided transoesophageal biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T1-2 N0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Distribution of distant metastases from newly diagnosed non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection--pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized trial of surgery in the treatment of single metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cost-effectiveness of Head CT in Patients With Lung Cancer Without Clinical Evidence of Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Regional lymph node classification for lung cancer staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Curative radiotherapy of early operable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Palliative radiotherapy for lung cancer: two versus five fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Massive haemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative chemotherapy for lung cancer does not increase surgical morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Duration of chemotherapy in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Patients at risk of chemotherapy-associated toxicity in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Chemotherapy in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Social consequences of brain or liver relapse in small cell carcinoma of the bronchus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Sequelae in long-term survivors of small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Pulmonary preinvasive neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Bronchogenic Carcinoma Presenting as an Endobronchial Mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Autofluorescence of normal and malignant bronchial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Early localization of bronchogenic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

New incoherent autofluorescence/fluorescence system for early detection of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Development of the autofluorescence endoscope imaging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Outcome of bronchial carcinoma in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A biological staging model for operable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Pretreatment Evaluation of Non–Small-cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cancer and tobacco smoking; a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Declining lung cancer rates among young men and women in the United States: a cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Lung cancer detected during a screening program using four-month chest radiographs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Miss rate of lung cancer on the chest radiograph in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Screening for lung cancer with low-dose spiral computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Screening for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Spiral computed tomography screening for lung cancer is ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Screening for lung cancer with CT: a preliminary cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prospects for lung-cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Management of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Solitary pulmonary nodules. CT-bronchoscopic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Chest wall and mediastinal invasion by lung cancer: evaluation with multisection expiratory dynamic CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Accuracy of computed tomography and magnetic resonance imaging in staging bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Superior sulcus tumors: CT and MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Evaluation of primary pulmonary carcinoid tumors using FDG PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Comparison of rigid and flexible transbronchial needle aspiration in the staging of bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

US-assisted bronchoscopy with use of miniature transducer-containing catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Role of transesophageal endosonography-guided fine-needle aspiration in the diagnosis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The clinical evaluation for detecting metastatic lung cancer. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Frequency of extrathoracic metastases from bronchogenic carcinoma in patients with normal-sized hilar and mediastinal lymph nodes on CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1,020 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The role of curative radiotherapy in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

What have we accomplished in the management of patients with small cell anaplastic carcinoma of the lung?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Impact of tumor control on survival in carcinoma of the lung treated with irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Wor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial of neoadjuvant therapy for lung cancer: interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Inoperable non-small cell lung cancer: radiation with or without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Half-body and local chest irradiation as consolidation following response to standard induction chemotherapy for disseminated small cell lung cancer: An Eastern Cooperative Oncology Group Pilot Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Treatment of small cell lung carcinoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Bronchioloalveolar cell adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Bronchoscopic photodynamic therapy of early lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Endobronchial ultrasonography in the assessment of centrally located early-stage lung cancer before photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Tumor angiogenesis and recurrence in stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

The effect of thalidomide on experimental tumors and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200202-070SO

10.1164/RCCM.200202-070SO

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12403687%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference